Anna Törner: Success requires bold decisions!

“Doing things right is fine, but doing the right things as soon as possible is even better”, writes Anna Törner in a column.

Raised millions to develop a treatment for ´butterfly children´

Fragile as a butterfly’s wing – that’s how people living with Epidermolysis Bullosa are usually described. The Lund-based company Xinnate recently raised SEK 100 million in a new...

NorthX Biologics Matfors AB

Marie Gårdmark: Potential step change – EU regulators get to play with data

A new pilot from EMA is starting in September to assess wether the analysis of 'raw data' by regulatory authorities improves the evaluation of marketing approval for new medicines. Marie Grådmark writes in a column that she is looking forward...

The first Lyme disease vaccine faces a delay

Pfizer and Valneva’s Lyme disease vaccine, which could be the first of its kind, is facing delays of about a year. The reason is problems at trial sites in the ...

The Swedish Academy of Sciences: “We have too many researchers”

Sweden does not need more researchers, but it does need better ones. According to the Royal Swedish Academy of Sciences, funding should be distributed to favour excellence.

Webinar: Automate your processes

Free ZEISS webinar on January 30th, 2025.

ProPharma

Before you choose a CRO

– We are a small company and it is very important for us to maintain our core competence within development of novel nanomaterials, Tove Sivik Sonne, Head of De...

Affibody AB

Takeover bid is being completed – Japanese company acquires Calliditas

Japanese company Asahi Kasei completes the bid for Calliditas Therapeutics after reaching over 90 percent of the shareholding. Callidita's board has now decided...

The future of healthcare in focus: ”Together, things happen”

In march, it’s once again time for Fokus Patient, an event for the industry where the patients’ perspective takes center stage. It’s a great way to spread knowl...

IVI’s Director General on establishing in Sweden: Will need up to 40 employees

The International Vaccine Institute, IVI, hopes to have its first staff on-site in Stockholm within a couple of months, says the institute’s Director General Je...

Artificial intelligence in radiology – “Risk prediction is very exciting”

A growing number of solutions based on artificial intelligence are being developed and used in healthcare. According to Sophia Zackrisson, Professor of Radiolog...

A green nursery for biotech rooted in the Scanian soil

Red Glead has established itself as one of Lund’s largest companies in pharmaceutical development. Life Science Sweden went to Skåne and met two of the founders...

Metabolon

He is zooming in on topical preparations

According to Zelmic CEO David Sagna, topical products in drug development is a growing market, and to keep pace with the development, the company is awaiting approval for its new...

No demand for new Covid vaccine – “It will probably be discarded”

So far, just under 6 000 doses of the Covid vaccine from Novavax have been used in Sweden, leaving over 1.4 million doses in stock. “They will probably be disca...

AZ gets approval for drug targeting rare disease – it may reduce cortisone dependence

AstraZeneca’s drug Fasenra gets an expanded indication in the EU and is now approved as a treatment for the rare autoimmune disease known as Churg-Strauss syndrome.

Helena Strigård: The rise of the community

Sweden Bio´s CEO is looking back at the last decade of development in the industry. Something has shifted in the interdependence between small and larger companies.

Italian pharmaceutical company buys rights to immunotherapy from Sanofi

Italy's Recordati buys the rights to a treatment for the rare autoimmune disease cold agglutinin disease (CAD).

CTC Clinical Trial Consultants AB

The most important Swedish medical innovations: Our ranking

Life Science Sweden turns 20 years old – and celebrates by producing a top list of the 20 most important contemporary Swedish innovations in the field of medicine.

Sustainability at Festo

On the Way to the Net Zero Era - New Sustainability Report published